Skip to content

Tear biomarkers for Alzheimer's disease (AD) screening and diagnosis

Tear biomarkers for Alzheimer's disease (AD) screening and diagnosis - TearAD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56224
Enrollment
200
Registered
2020-04-24
Start date
2022-06-09
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease cognitive decline dementia memory problems

Interventions

Sponsors

Maastricht Universitair Medisch Centrum +
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria:  Written informed consent obtained and documented  Capable of giving informed consent themselves (MMSE score > 17/30)* 

Exclusion criteria

Exclusion criteria:  Ocular conditions that could influence tear biochemical parameters (including  eye infection, eye inflammation, eye surgery within the last 28 days or other  acute eye conditions) Neurological or systemic chronic conditions known to interfere with retinal  thickness (e.g., glaucoma, diabetes mellitus) Ocular conditions interfering with OCT quality/retinal thickness: e.g. severe  cataract, age-related macular degeneration, and glaucoma 

Design outcomes

Primary

MeasureTime frame
The main study parameter is the difference in level of tear biomarkers (such as amyloid-beta and tau) between patients and controls, and between patient groups.

Secondary

MeasureTime frame
The correlation between tear biomarkers with CSF and blood biomarkers. The correlation between tear biomarkers and other ocular imaging biomarkers

Countries

Netherlands

Contacts

Public ContactM Gijs

Maastricht Universitair Medisch Centrum +

marlies.gijs@mumc.nl0618064496

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)